Income Statement
SAB BIOTHERAPEUTICS, INC.
SABS
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY |
|---|---|---|---|---|---|---|
|
Revenue
|
0.00 | 1.32 | 2.24 | 23.90 | 60.88 | - |
|
Cost of Revenue
|
- | - | - | - | - | - |
|
Gross Profit
|
- | 1.32 | 2.24 | 23.90 | 60.88 | - |
|
Operating Expenses
|
48.95 | 44.23 | 40.31 | 52.82 | 74.27 | 0.00 |
|
Research & Development
|
34.35 | 30.25 | 16.52 | 36.44 | 57.18 | - |
|
Selling, General & Administrative
|
14.60 | 13.98 | 23.80 | 16.38 | 17.09 | - |
|
Other Operating Expenses
|
- | - | - | - | - | - |
|
Operating Income
|
-48.95 | -42.91 | -38.08 | -28.92 | -13.39 | - |
|
Non-Operating Income
|
62.23 | 8.81 | -4.12 | 10.20 | 60.20 | - |
|
Interest Income
|
1.43 | 1.29 | 0.58 | 0.07 | 0.02 | - |
|
Interest Expense
|
- | - | 0.32 | 0.30 | 0.29 | - |
|
Other Non-Op Income / Expense
|
- | - | - | 0.03 | 0.01 | - |
|
Income Before Tax
|
13.27 | - | -42.19 | -18.72 | -17.14 | - |
|
Income Tax Expense
|
- | - | 0.00 | 0.03 | - | - |
|
Non-Controlling Interest
|
- | - | - | - | - | - |
|
Net Income
|
13.27 | -34.11 | -42.19 | -18.74 | -17.14 | - |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY |
|---|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - | - |
|
EBITDA
|
-45.95 | -38.20 | -34.38 | -25.75 | -11.90 | 0.00 |
|
Earnings Per Share (Basic)
|
0.22 | -3.68 | -7.64 | -0.43 | -0.63 | - |
|
Diluted EPS
|
-0.79 | -3.68 | -7.64 | - | -0.63 | - |
|
Weighted Average Shares
|
19.31 | 9.26 | 5.52 | 43.52 | 27.34 | - |
|
Diluted Weighted Avg Shares
|
61.34 | 9.26 | 5.52 | - | 27.34 | - |
|
Comprehensive Income
|
13.60 | -34.27 | -42.17 | - | - | - |